Trends in Suspected Fentanyl-Involved Nonfatal Overdose Emergency Department Visits, by Age Group, Sex, and Race and Ethnicity - United States, October 2020-March 2024.

Morbidity and Mortality Weekly Report Pub Date : 2025-05-08 DOI:10.15585/mmwr.mm7416a2

Cassandra M Pickens,Joohyun Park,Shannon M Casillas,Stephen Liu,Michael Sheppard,Erin K Stokes,Jean Y Ko,Seung Hee Lee

{"title":"Trends in Suspected Fentanyl-Involved Nonfatal Overdose Emergency Department Visits, by Age Group, Sex, and Race and Ethnicity - United States, October 2020-March 2024.","authors":"Cassandra M Pickens,Joohyun Park,Shannon M Casillas,Stephen Liu,Michael Sheppard,Erin K Stokes,Jean Y Ko,Seung Hee Lee","doi":"10.15585/mmwr.mm7416a2","DOIUrl":null,"url":null,"abstract":"Fatal overdoses involving synthetic opioids such as fentanyl increased sharply during the past decade. Recent data indicate declines in deaths with illegally manufactured fentanyls detected beginning in mid-2023. However, timely data on nonfatal overdoses involving fentanyl are limited. Emergency department (ED) data from CDC's National Syndromic Surveillance Program during October 2020-March 2024 were analyzed. Quarterly trends in rates of suspected nonfatal overdose of unintentional or undetermined intent involving fentanyl or fentanyl analogs (fentanyl-involved nonfatal overdoses) (i.e., the number of ED visits for fentanyl-involved nonfatal overdose per 10,000 total ED visits) were analyzed overall and by age group, sex, and race and ethnicity. During quarter (Q) 4 (October-December) 2020 to Q3 (July-September) 2023, rates of fentanyl-involved nonfatal overdose ED visits increased 8.7% per quarter, from 1.4 to 3.5 per 10,000 ED visits, then declined 11.0% per quarter, to 2.9 per 10,000 ED visits, from Q3 2023 to Q1 (January-March) 2024. Trends increased among a majority of demographic groups through mid-2023, with the highest rates and the largest increases among non-Hispanic American Indian or Alaska Native persons (e.g., 11.9 per 10,000 ED visits in Q3 2023, and an average quarterly increase of 9.0%, respectively). Providers in EDs have an important role in preventing fentanyl-involved nonfatal overdoses. Buprenorphine, a medication used to treat opioid use disorder that can be initiated in an ED, might benefit persons who use EDs as a main source of medical care. In addition, comprehensive services, including screening and treatment of co-occurring mental health conditions, as well as evidence-based prevention, treatment, and recovery support services, might be initiated in EDs because these might be particularly important in communities at high risk for fentanyl overdoses.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"48 1","pages":"282-287"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Morbidity and Mortality Weekly Report","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15585/mmwr.mm7416a2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Fatal overdoses involving synthetic opioids such as fentanyl increased sharply during the past decade. Recent data indicate declines in deaths with illegally manufactured fentanyls detected beginning in mid-2023. However, timely data on nonfatal overdoses involving fentanyl are limited. Emergency department (ED) data from CDC's National Syndromic Surveillance Program during October 2020-March 2024 were analyzed. Quarterly trends in rates of suspected nonfatal overdose of unintentional or undetermined intent involving fentanyl or fentanyl analogs (fentanyl-involved nonfatal overdoses) (i.e., the number of ED visits for fentanyl-involved nonfatal overdose per 10,000 total ED visits) were analyzed overall and by age group, sex, and race and ethnicity. During quarter (Q) 4 (October-December) 2020 to Q3 (July-September) 2023, rates of fentanyl-involved nonfatal overdose ED visits increased 8.7% per quarter, from 1.4 to 3.5 per 10,000 ED visits, then declined 11.0% per quarter, to 2.9 per 10,000 ED visits, from Q3 2023 to Q1 (January-March) 2024. Trends increased among a majority of demographic groups through mid-2023, with the highest rates and the largest increases among non-Hispanic American Indian or Alaska Native persons (e.g., 11.9 per 10,000 ED visits in Q3 2023, and an average quarterly increase of 9.0%, respectively). Providers in EDs have an important role in preventing fentanyl-involved nonfatal overdoses. Buprenorphine, a medication used to treat opioid use disorder that can be initiated in an ED, might benefit persons who use EDs as a main source of medical care. In addition, comprehensive services, including screening and treatment of co-occurring mental health conditions, as well as evidence-based prevention, treatment, and recovery support services, might be initiated in EDs because these might be particularly important in communities at high risk for fentanyl overdoses.

查看原文本刊更多论文

2020年10月至2024年3月，美国按年龄组、性别、种族和民族划分的疑似芬太尼非致命性过量急诊就诊趋势

在过去十年中，芬太尼等合成阿片类药物的致命过量使用急剧增加。最近的数据表明，从2023年中期开始，非法制造芬太尼的死亡人数有所下降。然而，涉及芬太尼的非致命性过量用药的及时数据有限。分析了2020年10月至2024年3月期间CDC国家综合征监测计划的急诊科（ED）数据。按年龄组、性别、种族和民族对芬太尼或芬太尼类似物（芬太尼相关非致命过量）的非致死性非故意或未确定意图的疑似过量的季度趋势进行了总体分析（即，每10000次ED访问中芬太尼相关非致死性过量的ED访问次数）。从2020年第四季度（10月至12月）到2023年第三季度（7月至9月），芬太尼相关的非致命性过量ED就诊率每季度增加8.7%，从1.4次到3.5次/万次ED就诊，然后从2023年第三季度到2024年第一季度（1月至3月），每季度下降11.0%，至2.9次/万次ED就诊。到2023年中期，大多数人口群体的趋势都有所增加，非西班牙裔美国印第安人或阿拉斯加原住民的发病率最高，增幅最大（例如，2023年第三季度每10,000次ED就诊中有11.9次，平均季度增长率分别为9.0%）。急诊室的提供者在预防芬太尼相关的非致命性过量用药方面发挥着重要作用。丁丙诺啡是一种用于治疗阿片类药物使用障碍的药物，可在急诊科开始使用，可能使使用急诊科作为主要医疗保健来源的人受益。此外，综合服务，包括筛查和治疗同时发生的精神健康状况，以及基于证据的预防、治疗和康复支持服务，可以在急诊科开展，因为这些在芬太尼过量使用的高风险社区可能特别重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Morbidity and Mortality Weekly Report

自引率

0.00%

发文量